Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-08-20 02:02 UTC

BIOMED PULSE

Thursday, August 20, 2026

Your daily briefing on longevity, viruses, and new cures.

Not medical advice. Ground yourself in the sources.

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in the Democratic Republic of the Congo is now officially the largest Ebola outbreak ever recorded in DRC history, with sustained transmission and rapid geographic expansion driving case counts into the thousands. [1]

Overall mood: grave on the outbreak front, cautiously active on longevity science — statin and metformin trials for older adults are reshaping prescribing norms.

🦠 OUTBREAKS & VIRUSES

EBOLA (BUNDIBUGYO VIRUS) - DRC AND UGANDA: RECORD-BREAKING OUTBREAK

  • WHO's August 14 Disease Outbreak News (DON615) describes the Bundibugyo virus disease (BVD) outbreak in DRC as entering "a phase of intense transmission" and explicitly labels it the largest Ebola outbreak ever reported in the country. [1]
  • The outbreak, which began in Mongbwalu Health Zone, Ituri Province, has expanded beyond its original zone over the past two months, with sustained urban and cross-border transmission to Uganda now a defining feature. [2] [1]
  • As of July 15 (DON613), cumulative confirmed cases had reached 2,124 with 828 deaths confirmed in DRC; the trajectory since then has continued upward toward the August 14 update. [3]
  • CDC mobilized an international Ebola response as early as May 17, 2026, and enhanced airport screening was activated at Washington-Dulles and then Atlanta Hartsfield-Jackson airports. [4] [5]
  • CDC issued its most recent outbreak statement on July 10, 2026, confirming ongoing coordination with DRC and Uganda ministries of health. [6]

CYCLOSPORA - TACO BELL / ICEBERG LETTUCE: LARGE U.S. MULTI-STATE OUTBREAK

  • CDC confirmed on July 17, 2026 that shredded iceberg lettuce served at Taco Bell locations is the source of Cyclospora infections across five states, with 1,644 people reported sick. [7]
  • The outbreak subsequently expanded to four additional states as of July 24, 2026, broadening the geographic footprint significantly. [8]

SALMONELLA - JALAPEÑOS: ACTIVE U.S. FOOD SAFETY ALERT

  • CDC posted a multistate Salmonella food safety alert on August 5, 2026, linked to jalapeños; consumers are urged to check for recalled product. [9]

WEST NILE VIRUS - EARLY SEASON, RECORD U.S. CASES

  • CDC flagged an early West Nile season with record case counts as of July 1, 2026, urging mosquito bite prevention particularly during the July 4th holiday weekend. [10]

HANTAVIRUS (ANDES VIRUS) - M/V HONDIUS CRUISE SHIP: WINDING DOWN BUT MONITORED

  • WHO's fifth and most recent DON (DON611, July 2, 2026) on the Andes hantavirus outbreak linked to the M/V Hondius cruise ship confirmed the outbreak originated aboard the vessel as of May 2, 2026, with multiple confirmed cases across nationalities; CDC issued parallel response transcripts through late June 2026.

NIPAH VIRUS - KERALA, INDIA

  • WHO confirmed on June 25, 2026 (DON609) a single laboratory-confirmed case of Nipah virus (NiV) in an adult male in Kozhikode district, Kerala State, India, who developed neurological symptoms and was hospitalized on June 10, 2026.
  • The case is being monitored; Kerala has experienced prior NiV events and has established response protocols.

MEASLES - BANGLADESH: NATIONWIDE SURGE

  • WHO's DON598 (April 23, 2026) reported Bangladesh notified WHO of 19,161 suspected measles cases and 2,897 laboratory-confirmed cases across 58 of 64 districts in all eight divisions of the country.

AVIAN INFLUENZA A(H9N2) - ITALY

  • WHO DON597 (April 10, 2026) reported Italy's IHR focal point notified WHO of a human H9N2 case in an adult male returning from Senegal; next-generation sequencing confirmed influenza A(H9N2).

YELLOW FEVER - GLOBAL

  • WHO DON610 (June 24, 2026) noted that following increased Americas transmission in 2025, yellow fever activity persisted into 2026, with six countries reporting 79 human infections between January 1 and May 26, 2026.

KINDERGARTEN VACCINATION RATES - SLIGHT DECLINE

  • CDC released data on August 17, 2026 showing U.S. kindergarten vaccination rates remain high overall but recorded a slight 0.1% decline in coverage, a signal worth monitoring given broader measles resurgence globally.

🧬 LONGEVITY & AGING

STATINS IN ADULTS 75-PLUS: STOPPING MAY BE NON-INFERIOR

  • The SAGA/SITE multicentre, open-label, pragmatic, non-inferiority randomised trial published in Lancet Healthy Longevity examined discontinuation of statins for primary prevention of atherosclerotic cardiovascular disease in adults aged 75 or older.
  • The trial, led by Bonnet F and colleagues, represents a direct challenge to the default of continuing statins indefinitely in older primary-prevention patients and feeds directly into the growing deprescribing literature.
  • A linked editorial by Arya Nezhad S, Rastgou P, and Nanna MG in the same issue calls for "changing the conversation, not the default" on statin use in this age group.

METFORMIN FOR PHYSICAL FUNCTION IN OLDER ADULTS WITH OBESITY: MODEST BUT REAL SIGNAL

  • The DEMFOS randomised controlled trial (Nava MLD and colleagues, Lancet Healthy Longevity) tested metformin added to lifestyle intervention for physical function in older adults with obesity.
  • A linked editorial by Witham MD and McDonald C warns against "inflated expectations" while acknowledging the trial contributes meaningful data to the question of whether metformin can counter frailty trajectories in older obese individuals.

SENESCENCE IN OSTEOARTHRITIS: DUAL ANTIOXIDANT-EPIGENETIC STRATEGY

  • A study published in Bioactive Materials (An X, Cai H, Wu W et al.) demonstrated that combining antioxidant and epigenetic interventions synergistically attenuates the self-perpetuating senescence cycle in osteoarthritis, targeting the feedback loop between oxidative stress and epigenetic dysregulation in chondrocytes.
  • The approach targets a core mechanism of joint aging and could inform future disease-modifying osteoarthritis therapies.

EGFR LOSS IN SKELETAL STEM CELLS IMPAIRS FRACTURE HEALING IN AGED MICE

  • Research in Bioactive Materials (Hu Y, Wang Y, Chen Y et al.) found that loss of epidermal growth factor receptor (EGFR) activity in skeletal stem and progenitor cells is associated with impaired fracture healing in aged mice, identifying EGFR signaling as a potential rejuvenation target for bone repair in the elderly.

PUNICALAGIN AND BONE MESENCHYMAL STEM CELL SENESCENCE

  • Wang Y and colleagues (published in Regenerative Therapy) showed that punicalagin, a polyphenol found in pomegranate, alleviates senile osteoporosis by inhibiting senescence of bone mesenchymal stem cells via the NRF2/HO-1 antioxidant pathway in a mouse model.

LYSOSOMAL AMPK ACTIVATION FOR METABOLIC LIVER DISEASE

  • A study in Bioactive Materials (Zhu J, Sun T, Wei F et al.) showed that targeting the ROAM1 protein with UDP-GlcNAc nanosheets selectively activates lysosomal AMPK, resolving metabolic dysfunction-associated steatotic liver disease (MASLD) — a condition strongly linked to aging and metabolic syndrome.

POSITIVE LIFE ORIENTATION LINKED TO LOWER BLOOD PRESSURE IN OLDER ADULTS

  • A Finnish generational cohort study (Lääti A et al., Blood Press) using two cohorts born 20 years apart found that positive life orientation in older adults is associated with lower blood pressure, adding psychosocial factors to the modifiable risk landscape for cardiovascular aging.

CANINE EPIGENETIC AGING SLOWED BY MINIMALLY PROCESSED DIET

  • A pilot study (Chen A, Guo W, Krumbeck JA et al., Veterinary Record Open) found that a minimally processed, human-grade diet altered canine epigenetic aging markers, slowing biological aging in dogs — a model that researchers increasingly use as a proxy for studying diet-longevity interactions in mammals.

DEPRESCRIBING TRIALS: RATIONALE-FIRST FRAMEWORK PROPOSED

  • Two linked correspondence pieces in Lancet Healthy Longevity (Hwang CS, Boockvar KS, Steinman MA; and Van der Linden LR) argue that deprescribing clinical trials must establish a biological and clinical rationale before selecting trial design, warning that methodological shortcuts undermine the validity of findings in aging populations.

PEPTISLEEP AND SLEEP IN ADULTS WITH IMPAIRMENT

  • A randomised, placebo-controlled pilot study (Mohan NM, Keogh B et al., Sleep Medicine X) evaluated PeptiSleep, a peptide supplement, for sleep modification and biometric outcomes in adults with sleep impairment, contributing to the growing evidence base on sleep as a longevity lever.

💊 NEW CURES & APPROVALS

YESINTEK (USTEKINUMAB-KFCE) - BIOCON BIOLOGICS INC: BIOSIMILAR SUPPLEMENT APPROVED

  • Biocon Biologics Inc received a supplemental approval (BLA761406) for YESINTEK, containing ustekinumab-kfce, a biosimilar to Stelara (ustekinumab), which targets the IL-12/IL-23 pathway and is used in plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

ZAVZPRET (ZAVEGEPANT HYDROCHLORIDE) - PFIZER: SUPPLEMENTAL APPROVAL

  • Pfizer received a supplemental approval (NDA216386) for ZAVZPRET, containing zavegepant hydrochloride, a CGRP receptor antagonist nasal spray for acute migraine treatment.

LEROCHOL (LERODALCIBEP-LIGA) - LIB THERAPEUTICS INC: SUPPLEMENTAL APPROVAL

  • Lib Therapeutics Inc received a supplemental approval (BLA761427) for LEROCHOL, containing lerodalcibep-liga, a PCSK9 inhibitor fusion protein for lipid-lowering in adults with hypercholesterolemia or established cardiovascular disease.

BUPRENORPHINE/NALOXONE - MULTIPLE SPONSORS: WAVE OF GENERIC SUPPLEMENTS

  • Multiple manufacturers — including Mylan Technologies (ANDA207607, ANDA211785), Hikma (ANDA203326), Ascent Pharms Inc (ANDA219850), and Wes Pharma Inc (ANDA209069) — received supplemental approvals for buprenorphine hydrochloride/naloxone hydrochloride sublingual formulations for opioid use disorder treatment.
  • Solo buprenorphine supplements were also approved for Quagen (ANDA201066), Rubicon Research (ANDA090279), Hikma (ANDA078633), and Sun Pharm (ANDA201760).

NDA218328 - SEASONS BIOTECHNOLOGY (TAIZHOU) CO LTD: ORIGINAL APPROVAL TRACKED

  • An original NDA (NDA218328) filed by Seasons Biotechnology (Taizhou) Co Ltd received a tracked action (ORIG TA); full indication details are pending in the official record.

🧪 CLINICAL TRIALS

ANTI-TSLPR CAR-T CELLS FOR RELAPSED/REFRACTORY B-ALL (NCT07572136)

  • A new ClinicalTrials.gov registration (NCT07572136, posted August 19, 2026) studies anti-CRLF2-R/TSLPR chimeric antigen receptor T cells (TSLPR-CART) in participants with recurrent or refractory CRLF2-R/TSLPR-overexpressing B-cell acute lymphoblastic leukemia (B-ALL), targeting a mutation that makes the cancer highly treatment-resistant.

CAREGIVER BOOTCAMP FOR POST-DEMENTIA-DIAGNOSIS SUPPORT (NCT07006116)

  • Trial NCT07006116 (posted August 19, 2026) assesses a synchronous/asynchronous psychoeducation program designed to promote caregiving mastery immediately after a dementia diagnosis, measuring effects on both caregiver and care-recipient well-being.

PET IMAGING OF NORADRENERGIC TRANSMISSION IN ALZHEIMER'S (NCT07686393)

  • Trial NCT07686393 (posted August 19, 2026) tests a new radioactive tracer, 11C-ARMI, designed to image noradrenergic transmission in the brain, with Alzheimer's disease listed as a primary target condition.

BPL-1357 UNIVERSAL INFLUENZA VACCINE - H1N1 CHALLENGE (NCT07215858)

  • Trial NCT07215858 (posted August 19, 2026) tests BPL-1357, a broad-spectrum influenza vaccine candidate, in a controlled H1N1 human challenge model, with the goal of providing pandemic-ready protection beyond seasonal flu strains.

CIRCADIAN DISRUPTION AND CARDIOVASCULAR RISK IN YOUNG HYPERTENSIVES (NCT07770958)

  • Trial NCT07770958 (posted August 19, 2026) is a 14-day wrist actigraphy study in adults aged 18-45 with essential arterial hypertension, investigating whether circadian disruption independently elevates blood pressure and worsens cardiovascular risk profile.

MDMA-ASSISTED THERAPY FOR PTSD IN VETERANS (NCT05790239)

  • Trial NCT05790239 (active, updated August 19, 2026) is a randomized, double-blind, single-site Phase II study comparing MDMA-assisted therapy versus low-dose d-amphetamine-assisted therapy for moderate-to-severe PTSD in participants aged 18 and older.

TRANSCRANIAL NEUROMODULATION FOR SUBSTANCE USE DISORDER DECISION-MAKING (NCT06561828)

  • Trial NCT06561828 (updated August 19, 2026) investigates transcranial neuromodulation protocols targeting impaired learning and decision-making in people with substance use disorder, where altered reward circuitry drives drug-seeking behavior.

HOST-MICROBIOME INTERACTIONS REPOSITORY (NCT05656378)

  • Trial NCT05656378 (updated August 19, 2026) is building a longitudinal biorepository to study how the microbiome — the community of bacteria and microorganisms in and on the body — influences health and disease, a foundation for future longevity and aging research.

📢 PUBLIC HEALTH

NEW WORLD SCREWWORM RESPONSE: CDC EMERGENCY OPERATIONS CENTER ACTIVATED

  • CDC activated its Emergency Operations Center for the New World Screwworm (Cochliomyia hominivorax) response on June 12, 2026, a parasitic fly larva that can infest open wounds in humans and animals and was previously eradicated from the U.S.

INFANT BOTULISM LINKED TO POWDERED INFANT FORMULA: ONGOING ALERT

  • As of June 13, 2026, CDC issued a recall alert urging parents to immediately stop using all Nara Organics Whole Milk Organic Infant Formula, linked to an ongoing infant botulism outbreak investigation.

CDC FREE MIND CAMPAIGN: YOUTH SUBSTANCE USE AND MENTAL HEALTH

  • CDC launched the Free Mind campaign on August 5, 2026, providing teens with targeted resources about substance use and mental health as part of a national prevention effort.

KINDERGARTEN VACCINATION: SLIGHT COVERAGE DECLINE FLAGGED

  • CDC data released August 17, 2026 confirm kindergarten vaccination rates remain high nationally but show a 0.1% coverage decline — a signal warranting watch given the concurrent DRC/Bangladesh measles situations.

TIMOR-LESTE CERTIFIED MALARIA-FREE BY WHO

  • WHO certified Timor-Leste malaria-free on July 23, 2025, recognizing a nationwide elimination effort that began shortly after the country's independence in 2002 — a global public health milestone.

U.S. WITHDRAWAL FROM WHO: FORMAL NOTIFICATION ACKNOWLEDGED

  • WHO issued a formal statement on January 24, 2026 noting that the United States' notification of withdrawal from WHO "makes both the United States and the world less safe" and flagged that the issues will be considered by the WHO Executive Board and the World Health Assembly.
  • The U.S. formally completed its WHO withdrawal on January 22, 2026, citing COVID-19 failures, politicization, and a planned shift to bilateral health arrangements.

BIOMED PULSE is for informational purposes only. Consult a qualified healthcare provider for any medical decisions. All claims are grounded in official sources as cited.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  4. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  5. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  6. CDC Statement on Ebola Outbreak in the Democratic Republic of … — CDC Newsroom
  7. Shredded iceberg lettuce served at Taco Bell locations is sour… — CDC Newsroom
  8. Cyclospora outbreak linked to iceberg lettuce expanded to four… — CDC Newsroom
  9. CDC warns of <em>Salmonella</em> outbreak linked to jalapeños — CDC Newsroom
  10. CDC Encourages Americans to Stay Mosquito Bite-Free during Ame… — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260820-02-v61 · 2026-08-20 02:02 UTC · pulse.uzylab.com

Read next